Education Program in Myasthenia

Auto-immune Myasthenia Clinical Trial

— MG-ETP  

Official title:

Efficiency of a Therapeutic Patient Education Program in Myasthenia Gravis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04714658
• Other study ID #: 7534
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 22, 2021
• Est. completion date: May 22, 2025

Study information

• Verified date: November 2020
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patient therapeutic education (PTE) has become "a must" in the modern management of chronic diseases. Its main objective is to improve compliance with treatment and the application of preventive measures. The main goal of this study is to assess the influence of the therapeutic education program on the perception of the disease in patients with autoimmune myasthenia. Secondary objectives are to assess quality of life, patient satisfaction of the PTE program, the acquisition of therapeutic goals and the influence of therapeutic education on the evolution of autoimmune myasthenia Study team hypothesize that therapeutic education could improve the patient's perception of myasthenia and its quality of life. By improving patient's adherence to treatments and his knowledge of the disease, it could also improve the evolution of myasthenia gravis. Study team suppose that PTE program can reduce the absenteeism at work, the number and duration of hospitalizations, particularly those in intensive care units.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: May 22, 2025
• Est. primary completion date: May 22, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with generalized autoimmune myasthenia with Acetylcholine Receptor Antibodies (AChR Ab) or with antibodies to the muscle-specific receptor tyrosine kinase (MuSK Ab)
• Patient agreeing to participate in the therapeutic education program
• Signing consent
• Subject affiliated with a health insurance social protection regiment

Exclusion Criteria:

• Patients without serological confirmation of myasthenia or pure ocular form
• Patient with cognitive impairment or behavioral problems that, in the investigator's opinion, will compromise their ability to comply with study procedures
• Refusal of the patient to participate in the study
• Patient who has already benefited from the therapeutic education program in myasthenia
• Age < 18 y.o.
• Subject under safeguarding justice
• Subject under guardianship or under curatorship

Related Conditions & MeSH terms

• Auto-immune Myasthenia
• Muscle Weakness

Intervention

Other:
• Therapeutic Education
Each patient will participate in 1 to 3 PTE sessions. st group collective workshop : allow the patient to better understand autoimmune nd workshop : fatigue and techniques that enable its best management. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brief Illness Perception Questionnaire		6 month after the first visit